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Abstract
Background—Knowledge of the number of persons with chronic hepatitis C virus (HCV) 
infection in the United States is critical for public health and policy planning.
Objective—To estimate the prevalence of chronic HCV infection between 2003 and 2010 and to 
identify factors associated with this condition.
Design—Nationally representative household survey.
Setting—U.S. noninstitutionalized civilian population.
Participants—30 074 NHANES (National Health and Nutrition Examination Survey) 
participants between 2003 and 2010.
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Measurements—Interviews to ascertain demographic characteristics and possible risks and 
exposures for HCV infection. Serum samples from participants aged 6 years or older were tested 
for antibody to HCV; if results were positive or indeterminate, the samples were tested for HCV 
RNA, which indicates current chronic infection.
Results—Based on 273 participants who tested positive for HCV RNA, the estimated prevalence 
of HCV infection was 1.0% (95% CI, 0.8% to 1.2%), corresponding to 2.7 million chronically 
infected persons (CI, 2.2 to 3.2 million persons) in the U.S. noninstitutionalized civilian 
population. Infected persons were more likely to be aged 40 to 59 years, male, and non-Hispanic 
black and to have less education and lower family income. Factors significantly associated with 
chronic HCV infection were illicit drug use (including injection drugs) and receipt of a blood 
transfusion before 1992; 49% of persons with HCV infection did not report either risk factor.
Limitation—Incarcerated and homeless persons were not surveyed.
Conclusion—This analysis estimated that approximately 2.7 million U.S. residents in the 
population sampled by NHANES have chronic HCV infection, about 500 000 fewer than 
estimated in a similar analysis between 1999 and 2002. These data underscore the urgency of 
identifying the millions of persons who remain infected and linking them to appropriate care and 
treatment.
Primary Funding Source—None.
Hepatitis C virus (HCV) infection is a treatable but underrecognized and underdiagnosed 
disease. An estimated 130 to 170 million persons, 2% to 3% of the world’s population, are 
living with HCV infection, and almost 500 000 persons die of HCV-related conditions each 
year (primarily decompensated cirrhosis and liver cancer) (1). In the United States, previous 
estimates have consistently indicated that approximately 3 million or more persons have 
chronic HCV infection.
An analysis of 21 241 serum specimens from participants in NHANES (National Health and 
Nutrition Examination Survey), which provides nationally representative statistics on the 
health of the U.S. noninstitutionalized civilian population, indicated that 2.7 million persons 
(95% CI, 2.4 to 3.0 million persons) had chronic HCV infection between 1988 and 1994 (2). 
A similar analysis of 15 079 NHANES specimens between 1999 and 2002 estimated that 3.2 
million persons (95% CI, 2.7 to 3.9 million persons) had chronic HCV infection (3). These 
estimates do not include cases of chronic HCV not captured by NHANES, notably among 
homeless persons and persons who were incarcerated during the survey (4).
The Institute of Medicine recently concluded that it is essential to know the dimensions and 
direction of this epidemic, which has major implications for health burden and costs for the 
United States (5). Current treatment can cure HCV in a substantial proportion of persons 
who complete therapy, thereby decreasing the risk for hepatocellular carcinoma and all-
cause mortality. However, many persons infected with HCV remain untested and unaware 
of their infection, are unknown to the health care system, and are not captured in case-based 
surveillance because they are typically asymptomatic (6). Deaths among persons with HCV 
infection have superseded deaths in those with HIV infection (7).
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Surveillance for antibody to HCV (anti-HCV) and HCV RNA has been part of NHANES 
since the 1980s, although RNA testing for NHANES III was done retrospectively. 
Surveillance through such a large national survey presents the best measurement of the 
prevalence of anti-HCV and chronic HCV infection in the general U.S. population. 
Accordingly, using methods similar to analyses from 20 and 10 years ago (2, 3), we 
analyzed data from participants in NHANES between 2003 and 2010 to estimate the 




The National Health and Nutrition Examination Survey, conducted by the Centers for 
Disease Control and Prevention’s National Center for Health Statistics, collects nationally 
representative data on the health and nutritional status of the U.S. noninstitutionalized 
civilian population. This survey uses a complex, stratified, multistage probability sampling 
design and collects information from approximately 5000 persons annually using 
standardized interviews, physical examinations, and tests of biological samples. Participants 
were interviewed in their homes using the interviewer-administered Computer-Assisted 
Personal Interviewing system to ascertain demographic characteristics and in the Mobile 
Examination Center to ascertain possible risks and exposures for HCV infection.
Context
Chronic hepatitis C virus (HCV) infection is an important public health issue. Using data 
from a U.S. household survey conducted between 2003 and 2010, the authors compared 
the estimated prevalence of chronic HCV infection and risk factors for infection with 
those from earlier periods.
Contribution
The estimated prevalence of chronic HCV infection in the United States has decreased. 
Risk factors are essentially unchanged from previous periods and were reported by only 
about one half of infected persons.
Caution
Homeless and incarcerated persons were not surveyed.
Implication
The burden of chronic HCV infection in the United States is substantial. National data on 
prevalence are useful for the design of programs for HCV screening, linkage to care, and 
treatment.
—The Editors
Persons aged 16 years or older and emancipated minors were interviewed directly; an adult 
proxy provided information for participants younger than 16 years and for persons unable to 
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answer the questions themselves. All participants provided written informed consent. More 
detailed information on survey design for NHANES, including approval from the National 
Center for Health Statistics Institutional Review Board (Hyattsville, Maryland), is available 
from the survey documentation at www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm.
Laboratory Testing
Qualitative determination of anti-HCV in blood serum or plasma was measured using direct 
solid-phase enzyme immunoassay with an anti-HCV screening chemiluminescence 
immunoassay (VITROS Anti-HCV Immunodiagnostic System, Ortho Clinical Diagnostics, 
Rochester, New York). Screening reactive specimens were then tested using a confirmatory 
recombinant immunoblot assay (RIBA) (RIBA HCV 3.0 Strip Immunoblot Assay, Chiron, 
Emeryville, California), an in vitro qualitative immunoassay for the detection of anti-HCV 
in human serum or plasma. Samples with positive results on RIBA testing were reported as 
confirmed positive for anti-HCV, those with results that were negative were reported as 
negative for anti-HCV, and those with indeterminate results were reported as indeterminate.
In clinical practice, it is most important to identify persons who are currently infected; 
however, for surveillance purposes, we are interested in having a reliable measure of both 
those who are currently infected and those who were ever infected. Although the sensitivity 
and specificity of anti-HCV tests have improved over time for at-risk populations, 
estimating the true prevalence in a low-risk, low-prevalence population, such as that 
sampled in NHANES, requires a confirmatory test, such as RIBA, to eliminate false-positive 
results from our estimates of persons ever infected. Serum samples that were confirmed 
positive or indeterminate for anti-HCV were further tested for HCV RNA using an in vitro 
nucleic acid amplification test for the quantitation of HCV RNA in human serum or plasma. 
We used the COBAS AMPLICOR HCV Test, version 2.0 (Roche Diagnostics, Indianapolis, 
Indiana), on the COBAS AMPLICOR Analyzer (Roche Diagnostics) for samples from 2005 
to 2010 and the COBAS AmpliPrep/ TaqMan HCV Test, version 2 (Roche Diagnostics), on 
the COBAS TaqMan 48 Analyzer (Roche Diagnostics) for samples from 2003 to 2004.
We considered persons to have chronic HCV infection if results of their test for anti-HCV 
were confirmed positive or indeterminate and results of their test for HCV RNA were 
positive. Our comparison group comprised persons who tested negative for anti-HCV; these 
participants were considered to be never infected with HCV. Those who tested positive for 
anti-HCV but negative for HCV RNA (resolved infections; n = 90) and those who had no 
serum available for RNA testing (n = 51) were not included in our analyses, except for 
estimation of overall anti-HCV prevalence, because we wanted to focus on chronic HCV 
infection.
Statistical Analysis
SAS-Callable SUDAAN, Release 10.0 (Research Triangle Institute, Research Triangle Park, 
North Carolina) (8), a statistical package designed to analyze complex survey data, was used 
for analysis. Estimates were weighted to represent the total U.S. noninstitutionalized civilian 
population and to account for oversampling and nonresponse to the household interview and 
physical examination. Two-year sample weights (WTMEC2yr) were further adjusted to 
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account for the fact that not all examination participants were tested for anti-HCV, not all 
participants who tested positive or indeterminate for anti-HCV had samples available for 
HCV RNA testing, and multiple years of data were used. A P value less than 0.05 was 
considered statistically significant.
We analyzed demographic characteristics (age at interview, sex, race/ethnicity, birthplace, 
education, and income), potential risk factors or exposures (receipt of blood or a blood 
product before 1992, any past injection drug use, and number of lifetime sexual partners), 
and a proxy for sexual risk (antibodies to herpes simplex virus type 2) (9, 10). Although sex 
is not a usual method of transmission of HCV infection (11), number of sexual partners and 
presence of herpes simplex virus type 2 antibodies are included because these are indices of 
increased likelihood of being infected with HCV and have been used in previous analyses. 
We restricted most analyses to persons aged 20 years or older because only 2 persons aged 6 
to 19 years had evidence of chronic HCV infection (that is, tested positive for HCV RNA) 
and because data on drug use and sexual behaviors among those younger than 20 years are 
not available from NHANES public-use data files. Ages included in our reporting of risks 
and exposures reflect age eligibility for a particular question or laboratory test rather than a 
focus on particular age groups.
We used bivariate analyses to estimate demographic characteristics of persons with chronic 
HCV infection and those who were never infected and to estimate the prevalence of 
potential risk factors or exposures among population subgroups. Chi-square tests were used 
for statistical comparisons between subgroups. Simple (unadjusted) and multivariate logistic 
regression analyses were used to identify factors associated with chronic HCV infection. We 
performed separate logistic analyses for persons aged 20 to 59 years and those aged 60 years 
or older because NHANES does not query those older than 59 years about sexual behaviors 
or drug use.
We retained 3 potential confounders—age at interview, sex, and race/ethnicity—in all 
multivariate models. Variables that were associated with HCV infection in previous 
NHANES analyses (2, 3) were included in multivariate models to identify factors 
independently associated with chronic HCV infection. Variables not included in the initial 
multivariate model building were added to the model individually to assess possible 
additional confounders. We excluded observations with missing covariate data from the 
corresponding analyses. We did not include markers for sexual behavior in the multivariate 
model for persons aged 20 to 59 years because sexual transmission of HCV has been 
documented primarily among HIV-infected men who have sex with men and rarely among 
monogamous heterosexual couples (11).
Role of the Funding Source
No external funding was received for this study.
RESULTS
Of the 43 898 persons aged 6 years or older sampled in NHANES between 2003 and 2010, a 
total of 34 039 (77.5%) were interviewed and 32 791 (96.3% of those interviewed) were 
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examined. Serum samples were available for anti-HCV testing for 30 074 persons (91.7% of 
those examined). Of these, 386 tested positive for anti-HCV and, of those who had 
additional serum available for HCV RNA testing (approximately 86%), 273 tested positive 
for HCV RNA.
Among the 30 114 persons aged 20 years or older sampled in NHANES between 2003 and 
2010, a total of 22 173 (73.6%) were interviewed and 21 281 (96.0% of those interviewed) 
were examined. Serum samples were available for anti-HCV testing for 20 042 persons 
(94.2% of those examined). Of these, 381 tested positive for anti-HCV; of those who had 
additional serum available for HCV RNA testing (approximately 87%), 271 tested positive 
for HCV RNA.
The estimated prevalence of anti-HCV among persons aged 6 years or older was 1.3% (95% 
CI, 1.2% to 1.5%), corresponding to approximately 3.6 million persons (CI, 3.0 to 4.2 
million persons) with past or current HCV infection in the general U.S. population. The 
estimated prevalence of HCV RNA among those aged 6 years or older was 1.0% (CI, 0.8% 
to 1.2%), corresponding to approximately 2.7 million persons (CI, 2.2 to 3.2 million 
persons) with chronic (current) HCV infection in the general U.S. population (Figure).
Demographic and Risk Characteristics of Persons With Chronic Infection
Compared with persons who were never infected with HCV, those with chronic HCV 
infection were more likely to be aged 40 to 59 years, male, of non-Hispanic black race/
ethnicity, and born in the United States. They were also less likely to have education past 
high school or family income at least twice the poverty level (Table 1). Of the estimated 
2.68 million chronically infected persons aged 20 years or older (CI, 2.18 to 3.19 million 
persons), we estimated that 1.09 million (CI, 780 000 to 1.40 million persons) were aged 40 
to 49 years, 1.03 million (CI, 770 000 to 1.28 million persons) were aged 50 to 59 years, 
1.71 million (CI, 1.29 to 2.13 million persons) were male, 1.64 million (CI, 1.19 to 2.10 
million persons) were non-Hispanic white, 2.52 million (CI, 2.03 to 3.02 million persons) 
were born in the United States, 1.04 million (CI, 740 000 to 1.33 million persons) had 
education beyond high school, and 1.11 million (CI, 760 000 to 1.46 million persons) had 
family income at least twice the poverty level. Among those born between 1945 and 1965, 
the estimated prevalence was 2.6% (CI, 2.1% to 3.2%), corresponding to an estimated 2.16 
million persons (CI, 1.70 to 2.61 million persons) with chronic HCV infection.
Persons aged 20 to 59 years with chronic HCV infection were more likely to have received a 
blood transfusion before 1992, ever injected illicit drugs, or had 10 or more lifetime sexual 
partners than those aged 20 to 59 years who never had HCV infection; however, only 50.8% 
reported a risk related to illicit injection drug use or transfusion. Persons aged 60 years or 
older with chronic HCV infection were more likely to have received a blood transfusion 
before 1992 than those of the same age who never had HCV infection.
Among persons aged 20 to 49 years, those with chronic HCV infection were more likely to 
be positive for antibody to herpes simplex virus type 2 than those who were never infected 
with HCV (Table 2). Because only 3 persons with chronic HCV infection tested positive for 
antibody to HIV, we were unable to produce reliable estimates for this variable. Of the 
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estimated 2.68 million chronically infected persons, 250 000 (CI, 120 000 to 380 000 
persons) aged 20 to 59 years and 130 000 (CI, 70 000 to 190 000 persons) aged 60 years or 
older were estimated to have received a blood transfusion before 1992, a total of 1.04 
million (CI, 760 000 to 1.32 million persons) were estimated to have ever injected illicit 
drugs, and 550 000 (CI, 340 000 to 770 000 persons) who reported no drug- or transfusion-
related risk were estimated to have had at least 10 lifetime sexual partners. An estimated 
1.19 million chronically infected persons aged 20 to 59 years (CI, 870 000 to 1.52 million 
persons) did not report illicit injection drug use or a transfusion-related risk.
Factors Associated With Chronic HCV Infection
Simple (unadjusted) logistic regression models for persons aged 20 to 59 years found that 
age 40 to 59 years, male sex, non-Hispanic black race/ethnicity, U.S. birth, high school 
education or less, and family income less than twice the poverty level were all statistically 
significantly associated with chronic HCV infection. Having ever used illicit drugs other 
than marijuana (including injection drugs), receipt of a blood transfusion before 1992, and 
having at least 10 lifetime sexual partners were also statistically significantly associated with 
chronic HCV infection. In the final multivariate logistic model, only receipt of a blood 
transfusion before 1992 did not remain statistically significantly associated with chronic 
HCV infection (Table 3).
Simple logistic models for persons aged 60 years or older found that age 60 to 69 years, 
non-Hispanic black race/ethnicity, and receipt of a blood transfusion before 1992 were 
statistically significantly associated with chronic HCV infection. Male sex was also 
statistically significantly associated with chronic HCV infection when added to the final 
main-effects multivariate logistic model (Table 4). Because male sex was statistically 
significantly associated with chronic HCV infection in the multivariate model but not its 
simple logistic model, first-order interactions between sex and the other 3 independent 
variables in the final model were investigated by adding each interaction term separately to 
the final main-effects model; none was found to be statistically significant. Of note, 
NHANES does not assess drug use or sexual behaviors in persons aged 60 years or older, 
which accounts for the difference in factors examined for the 2 age groups (persons aged 20 
to 59 years and ≥60 years).
DISCUSSION
Using NHANES data from 2003 to 2010, we estimated that 1.3% of persons in the general 
U.S. population, or about 3.6 million (CI, 3.0 to 4.2 million persons), had anti-HCV 
indicative of past or current infection with HCV and that 1.0% of persons in the general 
population, or about 2.7 million (CI, 2.2 to 3.2 million persons), have chronic HCV infection 
(that is, are HCV RNA–positive). Our analysis of recent survey data may suggest a decrease 
in NHANES-estimated anti-HCV prevalence from 1.8% between 1988 and 1994 (2) and 
1.6% between 1999 and 2002 (3). As previously assessed using NHANES, approximately 
3.9 million persons (CI, 3.1 to 4.8 million persons) between 1988 and 1994 (2) and 4.1 
million (CI, 3.4 to 4.9 million persons) between 1999 and 2002 were ever infected with 
HCV (anti-HCV–positive) (3). Our findings also suggest a possible decrease in chronic 
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HCV infection from 1.3%, or 3.2 million persons (CI, 2.7 to 3.9 million persons), between 
1999 and 2002 (3) (Figure). However, because of overlap in the 95% CIs of the survey 
estimates of persons who ever had HCV infection or chronic infection, any differences may 
represent the variability around estimates computed from a sample of the civilian 
noninstitutionalized U.S. population.
Although increased successful treatment of HCV infection might also cause a decrease in 
prevalence estimates since the last survey, all available current information indicates that no 
more than one half of persons with chronic HCV infection have been tested for anti-HCV; 
many who are anti-HCV–positive do not receive medical care or confirmatory HCV RNA 
testing; and, if positive, few to date have received antiviral therapy and achieved sustained 
virologic response indicative of cure (6, 12–14). Thus, differences in prevalence due to 
successful treatment are unlikely.
From 1999 to 2007, HCV-associated deaths as captured in vital records increased by 50% to 
15 106 in 2007 (7), and the annual number of deaths among HCV-infected persons is 
probably much higher when other HCV-associated deaths not captured in vital records and 
deaths from other causes are considered. Using the NHANES III Linked Mortality File, El-
Kamary and colleagues (15) estimated that 31 163 persons with chronic HCV infection in 
the general population died from all causes annually between 1988 and 2006; they 
considered this an underestimate. A recently presented analysis supports the idea that HCV 
is grossly underrecorded on death certificates, even when the main cause of death is liver-
related (16). Thus, mortality in HCV-infected persons seems to be much higher than 
suggested by the 16 000 to 17 000 death certificates with HCV noted on them. In addition, a 
recent study (17) reported substantial increases in hospitalizations for HCV.
An increase in mortality among HCV-infected persons could help explain the decrease in 
prevalence of chronic HCV infection. Our finding of equivalent decreases in persons who 
ever had HCV infection (anti-HCV–positive persons) and those who had chronic (current) 
infection (persons with detectable HCV RNA) supports the suggestion that mortality among 
chronically infected persons has increased. We would not expect decreases in both if 
treatment were substantially affecting prevalence, because successful treatment should result 
in a decrease in the number of persons who are HCV RNA–positive but not in the number of 
persons who are anti-HCV–positive.
Demographic characteristics and risk factors or exposures associated with chronic HCV 
infection in our analysis of NHANES data from 2003 to 2010 did not differ substantially 
from those previously found to be associated with ever having had infection with HCV (2, 
3). As in the previous NHANES analyses, injection drug use and receipt of a blood 
transfusion before 1992 remain important risk factors for HCV infection. Of interest, 
although simple (unadjusted results) logistic regression models for persons aged 20 to 59 
years found receipt of a blood transfusion before 1992 to be statistically significantly 
associated with chronic HCV infection, blood transfusion before 1992 was not found to be 
statistically significantly associated with chronic infection in the final multivariate logistic 
model for those aged 20 to 59 years. This is probably due to the fact that age and sex are 
more strongly associated with chronic HCV infection and that these factors were also 
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statistically significantly associated with receipt of a transfusion before 1992 (P < 0.001 and 
P = 0.005, respectively).
Because only about one half of persons aged 20 to 59 years with current HCV infection 
reported having at least 1 of these risk factors, risk-based screening alone is an incomplete 
approach to identifying chronically infected persons. Our analysis found that the prevalence 
of chronic HCV infection among persons in the general population born between 1945 and 
1965 (2.6%) is 6-fold greater than that of other adults, representing 81% of all persons 
chronically infected with HCV. For this reason, the Centers for Disease Control and 
Prevention recently augmented existing risk-based policies for HCV testing to recommend a 
1-time HCV test for all persons born during this period (18). With implementation of this 
strategy, approximately 800 000 persons currently unaware of their infection could be 
identified and linked to appropriate care and treatment, potentially averting approximately 
120 000 deaths (19).
A major limitation of NHANES is that it does not include homeless and incarcerated 
persons, who are probably at higher risk for HCV infection. Accordingly, considerations of 
the prevalence and effect of chronic HCV infection in the United States should supplement 
data from NHANES with those from populations with a higher risk for and prevalence of 
HCV infection, such as institutionalized (incarcerated) and homeless persons. Having only 
273 HCV RNA–positive participants imposed limitations on our analysis: It was not 
possible to provide statistically valid estimates by age, or by sex and age within race/
ethnicity, to perform a trend analysis or to produce an odds ratio for injection drug use 
separate from use of drugs other than marijuana. For this reason, we also did not perform an 
analysis of prevalence by birth year, especially because this effect has already been well-
documented (3).
Because only 90 participants were anti-HCV–positive and HCV RNA–negative, analyzing 
them as a separate subgroup was not possible. The fact that NHANES does not query 
persons aged 60 years or older on drug use or sexual behavior restricted our ability to 
investigate these risk behaviors to those aged 20 to 59 years. In addition, the unavoidable 
missing data on self-reported risk factors may limit our ability to generalize our findings to 
the entire population sampled by NHANES. We were unable to estimate the prevalence of 
HIV infection among those who had chronic HCV infection because only 3 participants with 
chronic HCV infection were also positive for HIV antibodies. Finally, because NHANES 
participants are allowed to opt out of HIV testing, the participants who were positive for 
HIV antibodies are almost certainly not representative of such persons even in the NHANES 
population.
The availability of new, direct-acting antiviral medications with higher success rates (20) 
creates an enormous opportunity to prevent morbidity and mortality among persons with 
chronic HCV infection. Additional antiviral regimens that do not require interferon and 
ribavirin are anticipated soon (21), potentially improving patient adherence and health 
outcomes. However, the health impact of advances in HCV therapy can be realized only 
when HCV-infected persons are tested, identified, and linked to appropriate care and 
treatment (22). Our study and others have found that persons with chronic HCV infection 
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are frequently poor and less educated, factors that could pose barriers to receipt of these 
costly novel HCV treatments. Improving HCV testing, care, and treatment will require a 
comprehensive set of implementation activities, including changes in health policies, 
reimbursement for care and treatment, community education, and provider training. In the 
future, health surveys and surveillance systems may need to monitor the burden of disease 
and the effect of strategies for HCV testing, care, and treatment.
In summary, we estimate that approximately 2.7 million persons in the civilian 
noninstitutionalized U.S. population sampled by NHANES continue to have chronic HCV 
infection. If HCV infections among high-risk populations not sampled by NHANES are 
taken into account, our estimated prevalence of chronic infection is conservative. An 
important public health implication is that our analysis suggests decreases in prevalence that 
probably reflect increasing mortality from HCV-related conditions. That these deaths largely 
occur in the age group born between 1945 and 1965 (7) (the “Baby Boom” generation) 
underscores the urgency of addressing this underappreciated national epidemic partly 
through implementation of the recent Centers for Disease Control and Prevention 
recommendation for 1-time screening for HCV infection and referral to appropriate care and 
treatment for persons in this birth cohort (18).
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Figure. Estimated prevalence of anti-HCV and HCV RNA in persons aged ≥6 y, according to 
NHANES III (1988–1994), NHANES 1999–2002, and NHANES 2003–2010
Estimated persons infected are reported in millions. Anti-HCV = antibody to HCV; HCV = 
hepatitis C virus; NHANES = National Health and Nutrition Examination Survey.
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Table 1
Demographic Characteristics by HCV Status for Participants Aged ≥20 y: NHANES 2003–2010 (n = 19 901)
Characteristic HCV Status P Value*
Anti-HCV–Negative HCV RNA–Positive
Participants, n Proportion (95% CI) Participants, n Proportion (95% CI)
Age at interview <0.001
 20–29 y 3501 19.3 (18.3–20.4) 5 1.2†‡ (0.3-5.2)
 30–39 y 3320 19.0 (18.1–19.9) 28 10.1 (6.4–15.6)
 40–49 y 3284 20.4 (19.5–21.4) 89 40.7 (34.0–47.8)
 50–59 y 2746 17.5 (16.7–18.4) 93 38.3 (31.6–45.4)
 ≥60 y 6779 23.8 (22.5–25.1) 56 9.7 (6.8–13.6)
Sex <0.001
 Male 9469 47.8 (47.2–48.5) 165 63.6 (56.1–70.6)
 Female 10 161 52.2 (51.5–52.8) 106 36.4 (29.4–43.9)
Race/ethnicity <0.001
 Hispanic 5184 12.5 (10.4–14.8) 47 9.6 (5.9–15.3)
 Non-Hispanic white 9819 70.3 (66.9–73.6) 112 61.3 (52.4–69.5)
 Non-Hispanic black 3734 11.2 (9.6–13.0) 103 25.3 (19.2–32.6)
 Other (including multiple races) 893 6.0 (5.1–7.0) 9 3.8†‡ (1.8-8.0)
Birthplace <0.001
 United States 14 819 83.4 (81.0–85.5) 253 94.1 (89.2–96.9)
 Other 4805 16.6 (14.5–19.0) 18 5.9‡ (3.1-10.8)
Highest education level <0.001
 Less than high school 5690 18.7 (17.5–20.0) 105 29.6 (24.0–36.0)
 High school/GED 4684 24.7 (23.6–25.9) 79 31.7 (24.2–40.2)
 More than high school 9228 56.6 (54.8–58.4) 86 38.7 (30.8–47.3)
Family income <0.001
 ≥2.0 times poverty level 9744 66.7 (64.9–68.5) 84 43.7 (35.7–52.0)
 1.0–1.9 times poverty level 4901 20.4 (19.3–21.6) 78 27.2 (21.2–34.3)
 Below poverty level 3551 12.9 (11.9–13.9) 93 29.1 (21.8–37.7)
Total 19 630 98.7 (98.5–98.9) 271 1.3 (1.1–1.5) –
Anti-HCV = antibody to HCV; HCV = hepatitis C virus; NHANES = National Health and Nutrition Examination Survey.
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*
P value for chi-square test of difference in characteristic by HCV status.
†
Estimate may be unstable and should be interpreted with caution because it is based on <10 HCV RNA–positive persons.
‡
Estimate may be unstable and should be interpreted with caution because the relative SE is >30%.
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Table 2
Potential Risk Factors and Exposures by HCV Status: NHANES 2003–2010*
Potential Risk Factor or Exposure HCV Status P Value†
Anti-HCV–Negative HCV RNA–Positive
Participants, n Proportion (95% CI) Participants, n Proportion (95% CI)
Blood transfusion before 1992
 Participants aged 20–59 y at interview 0.027
  Yes 486 4.2 (3.7–4.8) 24 10.5 (6.1–17.5)
  No 12 241 95.8 (95.2–96.3) 187 89.5 (82.5–93.9)
 Participants aged ≥60 y at interview <0.001
  Yes 894 14.8 (13.7–15.9) 21 52.6 (37.9–66.9)
  No 5644 85.2 (84.1–86.3) 32 47.4 (33.1–62.1)
Lifetime drug use‡ <0.001
 None or marijuana only 9248 79.4 (78.0–80.8) 51 26.5 (19.7–34.6)
 Only noninjection drugs 2070 19.0 (17.7–20.4) 42 22.0 (16.2–29.2)
 Injection drugs 158 1.6 (1.3–2.0) 89 51.5 (43.6–59.3)
Lifetime sexual partners‡ <0.001
 0–1 2286 18.8 (17.5–20.3) 10 3.7§ (1.7–7.8)
 2–9 5337 47.6 (46.3–48.9) 56 28.8 (21.5–37.5)
 10–19 1823 16.5 (15.5–17.5) 33 17.3 (12.4–23.5)
 20–49 1388 12.7 (11.8–13.6) 51 30.3 (23.6–38.0)
 ≥50 522 4.4 (3.9–4.9) 31 19.9 (13.2–28.8)
Antibody to herpes simplex virus type 
2∥
<0.001
 Positive 2161 18.3 (17.2–19.5) 63 52.8 (41.8–63.6)
 Negative 7800 81.7 (80.5–82.8) 57 47.2 (36.4–58.2)
Anti-HCV = antibody to HCV; HCV = hepatitis C virus; NHANES = National Health and Nutrition Examination Survey.
*
Sample sizes for each variable vary depending on age eligibility for a particular question or laboratory test.
†
P value for chi-square test of difference in the prevalence of the factor or exposure by HCV status.
‡
Participants aged 20 to 59 y at interview.
§
Estimate may be unstable and should be interpreted with caution because the relative SE is >30%.
∥
Participants aged 20 to 49 y at interview.
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Table 3






Final Multivariate Logistic Model
Adjusted Odds Ratio (95% CI) P Value
Age at interview
 20–39 y 5733 28 1.0 (reference) –
 40–49 y 2834 72 6.0 (3.2–11.1) <0.001
 50–59 y 2374 74 9.5 (5.3–16.8) <0.001
Sex
 Male 5292 109 1.6 (1.1-2.4)† 0.021
 Female 5649 65 1.0 (reference) –
Race/ethnicity
 Non-Hispanic black 2195 60 1.6 (1.1-2.3)† 0.018
 All others 8746 114 1.0 (reference) –
Birthplace
 United States 8326 164 1.0 (reference) –
 Other 2615 10 0.4 (0.2-0.9)† 0.027
Highest education level
 Less than high school/GED 5110 117 2.0 (1.2-3.3)† 0.007
 High school or more 5831 57 1.0 (reference) –
Family income
 <2.0 times poverty level 4937 121 3.7 (2.6–5.3) <0.001
 ≥2.0 times poverty level 6004 53 1.0 (reference) –
Lifetime drug use
 None or marijuana only 8706 49 1.0 (reference) –
 Other (including injection drugs) 2235 125 8.7 (5.9–12.8) <0.001
HCV = hepatitis C virus; NHANES = National Health and Nutrition Examination Survey.
*
Sample sizes from final model.
†
Estimate may be unstable and should be interpreted with caution because the relative SE is >30%.
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Table 4






Final Multivariate Logistic Model
Adjusted Odds Ratio (95% CI) P Value
Age at interview
 60–69 y 3035 35 2.0 (1.1–3.8)† 0.034
 ≥70 y 3556 18 1.0 (reference) –
Sex
 Male 3297 32 2.7 (1.4–5.4)† 0.005
 Female 3294 21 1.0 (reference) –
Race/ethnicity
 Non-Hispanic black 1129 28 10.0 (4.9–20.1) <0.001
 All others 5462 25 1.0 (reference) –
Blood transfusion before 1992
 Yes 915 21 8.5 (4.5–16.3) <0.001
 No 5676 32 1.0 (reference) –
HCV = hepatitis C virus; NHANES = National Health and Nutrition Examination Survey.
*
Sample sizes from final model.
†
Estimate may be unstable and should be interpreted with caution because the relative SE is >30%.
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